Bonum Therapeutics
Focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD507—761m (Dealroom.co estimates Nov 2022.)
Seattle Washington (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Corporate spinout | |
* | $93.0m | Series A | |
| Total Funding | CAD127m | ||